Christopher Mulder, DO
Gastroenterology · Clive, IANPI 1356577951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 348 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,687, 5.4 times the $310 reported in 2021. Among gastroenterology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$947
- Takeda Pharmaceuticals U.S.A., Inc.$670
- Regeneron Healthcare Solutions, Inc.$480
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$443
- Lilly USA, LLC$356
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,25799%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $1,374 |
| Johnson & Johnson | 52 | $947 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $670 |
| Regeneron Healthcare Solutions, Inc. | 24 | $480 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $443 |
| Lilly USA, LLC | 15 | $356 |
| Bristol Myers Squibb | 20 | $261 |
| Phathom Pharmaceuticals, Inc. | 7 | $222 |
| Pfizer | 11 | $168 |
| Amgen | 7 | $135 |
| Ironwood Pharmaceuticals, Inc | 7 | $129 |
| Ardelyx, Inc. | 5 | $121 |
| Aimmune Therapeutics, Inc. | 5 | $99 |
| Celltrion USA Inc. | 6 | $97 |
| Lumendi LLC | 1 | $93 |
| Merck | 5 | $89 |
| Ipsen Biopharmaceuticals, Inc | 3 | $83 |
| Gilead | 4 | $77 |
| QOL Medical, LLC | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 1 | $57 |
| Olympus Corporation Of The Americas | 1 | $48 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Sanofi | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Braintree Laboratories, Inc. | 2 | $32 |
| Boston Scientific | 1 | $30 |
| Intercept Pharmaceuticals, Inc. | 2 | $30 |
| Novo Nordisk | 1 | $27 |
| Organon | 3 | $25 |
| Micro-tech Endoscopy USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,290 in reported general payments places this provider in the 90th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $365,347 |
| RelistorMethylnaltrexone Bromide | 12 | $22,118 |
| LinzessLinaclotide | 21 | $11,255 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 105 | $6,504 |
| Budesonide DrBudesonide | 24 | $2,599 |
| Pantoprazole Sodium | 176 | $1,343 |
| Omeprazole | 91 | $684 |
| Dicyclomine Hcl | 13 | $457 |
| Sucralfate | 16 | $422 |
| Famotidine | 33 | $281 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 13 | $244 |
| Nortriptyline Hcl | 14 | $144 |
| Ondansetron Hcl | 68 | $75 |
| Ondansetron OdtOndansetron | 33 | $47 |
| Lansoprazole | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $947 | $365,34713 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $443 | $22,11812 claims |
| AbbVieLinzess | $1,374 | $11,25521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 gastroenterology providers in Iowa.
Other gastroenterology in Clive
- Nagendra MyneniClive$66K
- Bernard LemanClive$12K
- Archana VermaClive$6K
- Benjamin PottebaumClive$6K
- Amol AgarwalClive$6K
- Tercio LopesClive$5K
- Ravi VemulapalliClive$4K
- Thomas MartinClive$2K
- Rajalakshmi IyerClive$2K
- Jeffrey BrannenClive$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.